Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 15

Showing 15 citing articles:

The role of RNA methylation in tumor immunity and its potential in immunotherapy
Yan Li, Haoer Jin, Qingling Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 30
Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases
Christian Bailly, Xavier Thuru
Cancers (2023) Vol. 15, Iss. 7, pp. 2186-2186
Open Access | Times Cited: 22
The Potential Role of PD-1/PD-L1 Small Molecule Inhibitors in Colorectal Cancer with Different Mechanisms of Action
Suhaibee Kuno, Nattaporn Pakpian, Chatchai Muanprasat
European Journal of Pharmacology (2025), pp. 177351-177351
Closed Access
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Huan Zhang, Yuepeng Pang, Ling Yi, et al.
Clinical Epigenetics (2025) Vol. 17, Iss. 1
Open Access
A systematic and comprehensive analysis of T cell exhaustion related to therapy in lung adenocarcinoma tumor microenvironment
Peipei Hu, Jiahao Ma, Jinjian Chen
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
Zhi Li, Xi Yu, Zeting Yuan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189152-189152
Closed Access | Times Cited: 2
Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy
Simeng Wang, Mengjun Sui, Quan Chen, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 155074-155074
Open Access | Times Cited: 2
Diagnosis and Prognosis of Thyroid Cancer by Immune-related Genes
Jinze Li, Zhenjun Li, Ping Zhao
American Journal of Clinical Oncology (2023)
Closed Access | Times Cited: 5
Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design
Greta Donati, Vincenzo Maria D’Amore, Pasquale Russomanno, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 3355-3368
Open Access | Times Cited: 4
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein–Protein Interaction
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, et al.
Molecules (2024) Vol. 29, Iss. 11, pp. 2646-2646
Open Access | Times Cited: 1
pH-responsive self-assembling peptides potentiate therapeutic efficacy via prolonged drug retention and immunomodulation
Shan Peng, Xiaomeng Yuan, Hongjie Li, et al.
Materials & Design (2024) Vol. 241, pp. 112893-112893
Open Access
Industry Update: the latest developments in the field of therapeutic delivery, July 2024
Peter Timmins
Therapeutic Delivery (2024) Vol. 15, Iss. 12, pp. 911-920
Open Access
Preparation and bioevaluation of a 99mTc-labeled small-molecular radiotracer for PD-L1 imaging
Xiang Xu, Yuanbing Mao, Peng Zhou, et al.
Journal of Radioanalytical and Nuclear Chemistry (2024)
Closed Access
Site-Selective Functionalized PD-1 Mutant for a Modular Immunological Activity against Cancer Cells
Silvia Fallarini, Linda Cerofolini, Maria Salobehaj, et al.
Biomacromolecules (2023) Vol. 24, Iss. 11, pp. 5428-5437
Open Access | Times Cited: 1
Interaction of telmisartan and related sartans with the programmed cell death-ligand 1 (PD-L1) protein dimer: a molecular docking analysis
Gérard Vergoten, Christian Bailly
Future Journal of Pharmaceutical Sciences (2023) Vol. 9, Iss. 1
Open Access
Page 1

Scroll to top